Selpercatinib is the first drug from Loxo’s pipeline that Lilly has brought to market. Prior to the acquisition, Loxo won approval of Vitrakvi, which targets a different genetic mutation and is sold by Bayer AG. The MD is manufactured by B-ON, and the company asserts that the device can measure a user’s electrocardiogram (EKG) activity, […]
READ MORE